FILTER

FILTERED INTERVIEW RESULTS

Robert Poe

CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."

Chris Garabedian

CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."

Jeff Olsen

CEO, BOART LONGYEAR
"I believe the increased drilling activity will continue into 2023, and we are anticipating strong business for the foreseeable future."

Keith Jones

GENERAL MANAGER, SMALL MINE DEVELOPMENT (SMD)
"We are open to working anywhere in the US where there are hard rock, metal, or non-metal, underground mines."

Tom Wilson

GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."

Fabrice Panza

MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO
"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."

Dagny Odell

OWNER, PRACTICAL MINING
"If you think about the end use and reclamation requirements early on and incorporate solutions early, it makes the project much more efficient and improves the final environmental outcome."

Mark Compton

EXECUTIVE DIRECTOR, AMERICAN EXPLORATION & MINING ASSOCIATION (AEMA)
"Put simply, without permitting reform it will be impossible to meet our nation’s mineral needs."

James Sapirstein

CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

USA Mining 2025-26 - Pre-release

USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.

PARTNER EVENTS